Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 801 - 900
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 801 | 25031417 |
US |
64 | 2 |
Cataract, Device difficult to use, Accidental exposure to product, Drug dose omission by device, Product communication issue, |
||||
EVOLOCUMAB, |
||||
| 802 | 25031852 |
US |
47 | 2 |
Pain, Accidental exposure to product, |
||||
FREMANEZUMAB-VFRM, |
||||
| 803 | 25031921 |
US |
81 | 2 |
Cerebrovascular accident, Device difficult to use, Accidental exposure to product, Product administration error, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, INSULIN DEGLUDEC, SEMAGLUTIDE, |
||||
| 804 | 25032216 |
GB |
43 | 2 |
Accidental exposure to product, Device leakage, Device breakage, Needle issue, |
||||
MEDROXYPROGESTERONE ACETATE, |
||||
| 805 | 25032627 |
US |
10 | 2 |
Device difficult to use, Accidental exposure to product, Feeling abnormal, Wrong technique in product usage process, |
||||
ETANERCEPT, |
||||
| 806 | 25032738 |
US |
38 | 2 |
Urticaria, Accidental exposure to product, |
||||
IBUPROFEN, |
||||
| 807 | 25032878 |
US |
2 | |
Device malfunction, Accidental exposure to product, Drug dose omission by device, |
||||
SECUKINUMAB, |
||||
| 808 | 25032918 |
US |
1 | |
Accidental exposure to product, Device malfunction, Device leakage, Exposure via skin contact, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, |
||||
| 809 | 25033454 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 810 | 25033515 |
US |
74 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 811 | 25033541 |
US |
9 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 812 | 25033572 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 813 | 25033589 |
US |
14 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 814 | 25033605 |
US |
51 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 815 | 25033610 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 816 | 25033635 |
US |
13 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 817 | 25033648 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 818 | 25033673 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 819 | 25033701 |
US |
19 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 820 | 25033752 |
US |
76 | 2 |
Device difficult to use, Accidental exposure to product, Injection site pain, Drug dose omission by device, Off label use, |
||||
EVOLOCUMAB, TIRZEPATIDE, |
||||
| 821 | 25033833 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 822 | 25033839 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 823 | 25033975 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 824 | 25033985 |
US |
2 | |
Impaired quality of life, Erythema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, LEVOTHYROXINE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, BUPRENORPHINE, ALBUTEROL SULFATE, VENLAFAXINE HYDROCHLORIDE, GABAPENTIN, |
||||
| 825 | 25026911 |
US |
||
Accidental exposure to product, Occupational exposure to product, Device electrical finding, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 826 | 25028447 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 827 | 25028448 |
US |
2 | |
Skin exfoliation, Pruritus, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 828 | 25028728 |
CN |
||
Accidental exposure to product, Product dose omission issue, Device deployment issue, |
||||
GUSELKUMAB, |
||||
| 829 | 25028863 |
US |
47 | 2 |
Accidental exposure to product, Incorrect dose administered by product, Injection site pain, |
||||
ETANERCEPT, |
||||
| 830 | 25028935 |
US |
2 | |
Eye pruritus, Eyelid margin crusting, Dark circles under eyes, Product delivery mechanism issue, Accidental exposure to product, Exposure via skin contact, Circumstance or information capable of leading to medication error, |
||||
LATANOPROST, |
||||
| 831 | 25028960 |
US |
||
Accidental exposure to product, |
||||
SEVOFLURANE, |
||||
| 832 | 25026146 |
US |
80 | |
Glycosylated haemoglobin, Skin injury, Needle issue, Device delivery system issue, Incorrect dose administered, Device issue, Accidental exposure to product, |
||||
EXENATIDE, |
||||
| 833 | 25026171 |
US |
34 | 2 |
Wrong technique in product usage process, Incorrect dose administered, Accidental exposure to product, Injection site haemorrhage, |
||||
ERENUMAB-AOOE, |
||||
| 834 | 25026246 |
US |
52 | 2 |
Wrong technique in product usage process, Drug dose omission by device, Injection site erythema, Accidental exposure to product, Device difficult to use, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 835 | 25026584 |
US |
2 | |
Accidental exposure to product, Product dose omission issue, Needle issue, |
||||
SECUKINUMAB, |
||||
| 836 | 25026648 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 837 | 25026649 |
US |
57 | 1 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 838 | 25026663 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 839 | 25026665 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 840 | 25026678 |
US |
73 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 841 | 25026682 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 842 | 25026690 |
US |
63 | 2 |
Rebound atopic dermatitis, Product dose omission issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 843 | 25026705 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 844 | 25026719 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 845 | 25026732 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 846 | 25026739 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 847 | 25026749 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 848 | 25026751 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 849 | 25026753 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 850 | 25026764 |
US |
32 | 2 |
Peripheral swelling, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 851 | 25026766 |
US |
24 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 852 | 25026815 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 853 | 25026832 |
US |
36 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 854 | 25026858 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 855 | 25026868 |
US |
52 | 2 |
Product dose omission in error, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 856 | 25026871 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 857 | 25026884 |
US |
||
Skin swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 858 | 25026930 |
US |
65 | 2 |
Pruritus, Injection site pain, Therapeutic response delayed, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, BUMETANIDE, LEVOTHYROXINE, TIRZEPATIDE, SOLIFENACIN, SPIRONOLACTONE, |
||||
| 859 | 25026950 |
US |
44 | 2 |
Migraine, Scratch, Eczema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 860 | 25026955 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 861 | 25026987 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 862 | 25026989 |
US |
14 | 1 |
Depression, Eczema, Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 863 | 25027034 |
US |
68 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 864 | 25027065 |
US |
62 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 865 | 25027069 |
US |
75 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 866 | 25027088 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 867 | 25027115 |
US |
60 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 868 | 25027135 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 869 | 25027213 |
US |
48 | 1 |
Product dispensing issue, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 870 | 25027234 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 871 | 25027250 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 872 | 25027260 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 873 | 25027290 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 874 | 25027300 |
US |
84 | 1 |
Pertussis, Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
DUPILUMAB, MELATONIN, CLOPIDOGREL, CLOPIDOGREL BISULFATE, ERGOCALCIFEROL, FOLIC ACID, NITROGLYCERIN, BUDESONIDE, METOPROLOL TARTRATE, METOPROLOL, VITAMIN C, LEVOTHYROXINE, SUCRALFATE, SACUBITRIL AND VALSARTAN, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, IBUPROFEN TABLET COATED, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, CEFUROXIME, EMPAGLIFLOZIN, BUPROPION HYDROCHLORIDE, APIXABAN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, GABAPENTIN, |
||||
| 875 | 25027306 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 876 | 25027314 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 877 | 25027317 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 878 | 25027342 |
US |
||
Injury associated with device, Needle issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 879 | 25027359 |
US |
10 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 880 | 25027384 |
US |
2 | |
Cough, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, FLUTICASONE PROPIONATE, MONTELUKAST SODIUM, |
||||
| 881 | 25027399 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 882 | 25027442 |
US |
3 | 1 |
Skin fissures, Dry skin, Sleep disorder, Pruritus, Therapeutic response shortened, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 883 | 25027467 |
US |
44 | 2 |
Anxiety, Nasal congestion, Pyrexia, Migraine, Chest discomfort, COVID-19, Influenza, Oropharyngeal pain, Skin burning sensation, Condition aggravated, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, MONTELUKAST SODIUM, ALBUTEROL SULFATE, ALBUTEROL, OMALIZUMAB, |
||||
| 884 | 25027475 |
US |
8 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 885 | 25027477 |
US |
43 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 886 | 25027516 |
US |
75 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 887 | 25027521 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 888 | 25027522 |
US |
24 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 889 | 25027563 |
US |
57 | 2 |
Eye disorder, Blood glucose increased, Exposure via skin contact, Accidental exposure to product, |
||||
INSULIN GLARGINE, |
||||
| 890 | 25027657 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 891 | 25027678 |
US |
60 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, CALCIUM, ERGOCALCIFEROL, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ALBUTEROL SULFATE, SERTRALINE HYDROCHLORIDE, LORAZEPAM, AMLODIPINE BESYLATE, LOSARTAN POTASSIUM, LOSARTAN, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, |
||||
| 892 | 25027697 |
US |
11 | 2 |
Injection site erythema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 893 | 25027717 |
US |
63 | 2 |
Injection site swelling, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 894 | 25027741 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 895 | 25027750 |
US |
63 | 1 |
Injection site urticaria, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 896 | 25027759 |
US |
54 | 1 |
Inappropriate schedule of product administration, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, APIXABAN, AMLODIPINE BESYLATE AND VALSARTAN, |
||||
| 897 | 25027781 |
US |
64 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 898 | 25027791 |
US |
42 | 1 |
Injection site swelling, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, SULFASALAZINE, LOSARTAN POTASSIUM, LOSARTAN, ESCITALOPRAM OXALATE, ESCITALOPRAM, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 899 | 25027800 |
US |
19 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 900 | 25027856 |
US |
51 | 2 |
Accidental exposure to product, Exposure via skin contact, Dermatitis atopic, Incorrect dose administered, |
||||
DUPILUMAB, DESONIDE, ESCITALOPRAM OXALATE, ESCITALOPRAM, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, ALBUTEROL SULFATE, FLUTICASONE PROPIONATE, TIOTROPIUM BROMIDE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, LORATADINE, LORATADINE TABLET, CLINDAMYCIN HYDROCHLORIDE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28